Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans
The DOI matches its Crossref record.
Abstract
OBJECTIVES: To assess the pharmacologic effects and abuse liability of bretazenil, a partial benzodiazepine agonist, and compare them to the short-term effects of diazepam and alprazolam over a range of doses. METHODS: This was a placebo, within-subject, randomized, double-blind study conducted in 28 male volunteers. They were experienced but nondependent users of central nervous system depressants who had the ability to reliably distinguish 150 mg secobarbital from placebo and to report positive subjective effects. Subjects randomly received placebo and the two middle doses of diazepam, bretazenil, and alprazolam for the first 7 days of the study and, depending on their clinical response, received either the highest or the lowest dose of each drug for the remaining 3 days. Pharmacologic effects were assessed by use of objective tests (e.g., psychomotor performance), subject-rated questionnaires (e.g., Profile of Mood States), and observer-rated scales. RESULTS: All three drugs were clearly distinguishable from placebo on most measures. Diazepam and alprazolam produced dose-related psychomotor and memory impairment, whereas bretazenil produced a flatter slope. Both alprazolam and diazepam produced dose-dependent increases in subject and observer-rated sedation and liking, whereas bretazenil showed increases compared with placebo, but these effects were not dose dependent. CONCLUSIONS: Results from the study supported the view that bretazenil may have a partial agonist pharmacologic profile. Scores on subjective effects scales considered important for abuse liability assessment suggest a lower abuse liability of bretazenil than diazepam and alprazolam.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[51-73] Several of these dose.”
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2212-8 · Cited by 262
“1994) or humans (Busto et al. 1994).”
BackgroundTremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N., & Busto, U. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.409 · Cited by 229
Self-citationCheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“It seems that α 1 subtype should be completely avoided since even partial agonists at this site could still produce sedation and addiction as seen in bretazenil and MRK-409.(54,66) The increased AMPA/NMDA ratio in VTA has been shown in another GABA A PAM gaboxadol; however, it does not produce reinforcing effects.”
Metadata
- Authors
- Busto, U., Kaplan, H. L., Zawertailo, L., & Sellers, E. M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1994-04
- Volume
- 55
- Issue
- 4
- Pages
- 451-463
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2111775018
- Cited by
- 58
- References
- 0
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. https://app.cochat.ai/papers/10.1038/clpt.1994.55
- The paper
- Busto, U., Kaplan, H. L., Zawertailo, L., & Sellers, E. M. (1994). Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.1994.55
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.